Manns Braden, Tonelli Marcello, Yilmaz Serdar, Lee Helen, Laupland Kevin, Klarenbach Scott, Radkevich Val, Murphy Brendan
Department of Medicine, University of Calgary, Alberta, Canada.
J Am Soc Nephrol. 2005 Jan;16(1):201-9. doi: 10.1681/ASN.2004050355. Epub 2004 Nov 24.
Despite the importance of hemodialysis vascular access, the cost of vascular access care has not been studied in detail. A prospective cost analysis was performed among incident hemodialysis patients to determine the cost of vascular access care overall and on the basis of access type. Detailed clinical and demographic information, as well as data on access type, was collected for all local incident hemodialysis patients between July 1, 1999, and November 1, 2001. A comprehensive measure of total vascular access costs, including surgery, radiology, hospitalization for access complications, physician costs, costs for management of outpatient bacteremia, and vascular access monitoring costs, was obtained. Costs are reported in 2002 Canadian dollars (1 CAN dollar = 0.69 US dollar). A total of 239 consecutive incident hemodialysis patients were identified, 49, 157, and 33 of whom were dialyzed exclusively with a catheter or had a native arteriovenous fistula or synthetic graft attempted, respectively. In year 1, 18.4% of all hospital admissions were for vascular access-related complications. The mean cost of all vascular access care in year 1 was 6890 CAN dollars(median 4020 dollars; interquartile range [IQR] 2440 dollars to 7540 dollars). The mean cost of access care per patient-year at risk for maintaining a catheter exclusively, attempting an arteriovenous fistula, or attempting a graft was 9180 dollars (median 3812 dollars; IQR 2250 dollars to 7762 dollars), 7989 dollars (median 4641 dollars ; IQR 3035 dollars to 8832 dollars), and 11,685 dollars (median 8152 dollars; IQR 3395 dollars to 12,908 dollars), respectively (P = 0.01). Vascular access care is responsible for a significant proportion of health care costs in the first year of hemodialysis. These results support clinical practice guidelines that recommend preferential placement of a native fistula.
尽管血液透析血管通路很重要,但血管通路护理的成本尚未得到详细研究。对新接受血液透析的患者进行了一项前瞻性成本分析,以确定总体血管通路护理成本以及基于通路类型的成本。收集了1999年7月1日至2001年11月1日期间所有当地新接受血液透析患者的详细临床和人口统计学信息,以及通路类型数据。获得了血管通路总成本的综合衡量指标,包括手术、放射学、因通路并发症住院、医生成本、门诊菌血症管理成本以及血管通路监测成本。成本以2002年加元报告(1加元 = 0.69美元)。共确定了239例连续的新接受血液透析患者,其中49例、157例和33例分别仅使用导管进行透析或尝试建立自体动静脉内瘘或人工血管移植物。在第1年,所有住院患者中有18.4%是因血管通路相关并发症住院。第1年所有血管通路护理的平均成本为6890加元(中位数4020加元;四分位间距[IQR]为2440加元至7540加元)。仅维持导管、尝试建立动静脉内瘘或尝试建立人工血管移植物的每位患者每年的通路护理平均成本分别为9180加元(中位数3812加元;IQR为2250加元至7762加元)、7989加元(中位数4641加元;IQR为3035加元至8832加元)和11,685加元(中位数8152加元;IQR为3395加元至12,908加元)(P = 0.01)。血管通路护理在血液透析的第一年占医疗保健成本的很大比例。这些结果支持推荐优先建立自体内瘘的临床实践指南。